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Abstract 
 Clostridium sordellii is an emerging pathogen associated with highly-lethal female 
reproductive tract (FRT) infections following childbirth, abortion, or cervical 
instrumentation. Gaps in our understanding of the pathogenesis of C. sordellii infections 
present major challenges to the development of better preventive and therapeutic strategies 
against this problem. We sought to determine the mechanisms whereby uterine DMs 
phagocytose this bacterium and tested the hypothesis that human DMs utilize class A 
scavenger receptors (CASRs) to internalize unopsonized C. sordellii. In vitro phagocytosis 
assays with human DMs incubated with pharmacological inhibitors of CASRs (fucoidan, 
polyinosinic acid, and dextran sulfate) revealed a role for these receptors in C. sordellii 
phagocytosis. Soluble macrophage receptor with collagenous structure (MARCO) receptor 
prevented C. sordellii internalization, suggesting that MARCO is an important CASR in DM 
phagocytosis of this microbe. Peritoneal macrophages from MARCO-deficient mice, but not 
wild-type or SR-AI/II-deficient mice, showed impaired C. sordellii phagocytosis. MARCO-
null mice were more susceptible to death from C. sordellii uterine infection than wild-type 
mice and exhibited impaired clearance of this bacterium from the infected uterus. Thus, 
MARCO is an important phagocytic receptor utilized by human and mouse macrophages to 
clear C. sordellii from the infected uterus.  
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Chapter 1: Introduction 
   
A recent increase in Clostridium sordellii uterine infections in pregnant women 
following medical abortion, spontaneous abortion, or natural childbirth has sparked interest 
into the question of how these infections occurred. Although C. sordellii infections in the 
FRT are rare, they are highly and rapidly lethal.  Little is known about the pathogenesis of C. 
sordellii uterine infections, and even less is known about how innate immune cells of the 
uterus, such as DMs, interact with this anaerobic pathogen.  
The clostridia are anaerobic, spore-forming bacilli that cause a diverse array of toxin-
mediated infections in humans, including botulism, tetanus, and antibiotic-associated 
diarrhea. C. sordellii is an emerging pathogen associated with highly-lethal FRT infections, 
bacteremia, and soft tissue infections (2). The high mortality of C. sordellii infections is 
associated with a stereotypical toxic shock syndrome (5). A recent study estimated that 
nearly 1 in 200 deaths in women of reproductive age were associated with clostridial toxic 
shock, due to C. sordellii and/or the related C. perfringens (25). An increased number of 
severe C. sordellii infections has been reported over the past decade, following childbirth and 
abortion (21, 24, 43). Gaps in our understanding of the pathogenesis of C. sordellii infections 
present major challenges to the development of better preventive and therapeutic strategies 
against this emerging problem.  
In this light, we hypothesized that human DMs utilize CASRs to bind and 
internalize unopsonized C. sordellii. We further asked whether SR-AI/II and/or MARCO 
would be important receptor subtypes in this process. Alternatively, because class B 
scavenger receptors (CBSRs), and the macrophage mannose receptor, have also been 
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reported to be capable of phagocytosis of Gram-positive bacteria (35, 45), we questioned 
whether these receptors were also active in the clearance of C. sordellii.  
To address our major hypothesis and these related questions, we studied the 
expression of class A and B SR subtypes by human DMs and assessed their functional 
relevance in phagocytosis assays of C. sordellii in vitro. Macrophages derived from mice 
genetically lacking SR-AI/II or MARCO receptors were also used to examine the relevance 
of these receptors to immune clearance of C. sordellii. Last, a mouse model of C. sordellii 
uterine infection was utilized to define the importance of CASR subtypes in host defense. 
These studies shed new light onto the potential importance of CASRs in the innate immune 
defense against highly-lethal clostridial infections of the FRT.  
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Chapter 2: Background 
 
Clostridium sordellii 
The anaerobic, gram-positive bacterium Clostridium sordellii, though rarely a human 
pathogen, is increasingly recognized as a cause of acute, fulminant, and highly lethal 
infections. Progress in developing preventive and therapeutic strategies against this pathogen 
has been hampered by a lack of research into its ecology and pathogenesis. 
C. sordellii is rod-shaped and endospore-forming (40) and is normally found in the 
soil, within the intestinal flora of domestic animals, and has been estimated to colonize the 
gastrointestinal tract of 0.5% of humans (2). In animals (particularly cattle), a C. sordellii 
infection can cause fatal myositis, liver disease, enteritis, and sudden death. In humans it has 
been reported to cause pneumonia, endocarditis, arthritis, endometritis, peritonitis, 
myonecrosis, sepsis, toxic shock, and sudden death (3, 40). These infections have 
complicated various types of trauma, surgery, childbirth, spontaneous and medical abortion, 
and injection drug use, among others (2). Although in some cases the method of infection is 
known (e.g. the contamination of intravenously injected heroin or the transplantation of 
contaminated allograft materials), there are clinical scenarios for which the exact mechanism 
of infection remains speculative (e.g. following childbirth). 
The virulence of C. sordellii is attributed to the many toxins it is able to produce, 
including: lethal toxin, hemorrhagic toxin, hemolysin, neuraminidase, phospholipase C, 
DNAse, hyaluronidase, and collagenase. Of these eight toxins, the most significant and well 
studied is undoubtedly lethal toxin. 
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Human Decidual Macrophages 
Macrophages are important in defending the host against invasive clostridial 
infections (34), although the role of uterine macrophages in innate immune defense against 
clostridia is undefined. During pregnancy, uterine DMs participate in immunosurveillance, 
binding, ingesting, and clearing bacteria that ascend beyond the cervix (44). The receptor-
mediated mechanisms by which DMs recognize and phagocytose unopsonized bacteria, 
including clostridia, have not been closely analyzed.  
 
Clinical Significance 
In recent years, increases in cases of toxic shock syndrome due to C. sordellii 
infections following childbirth and abortion have been reported. These cases were usually 
accompanied by signs such as tachycardia, hypotension, edema, hemoconcentration, 
profound leukocytosis, and absence of fever (21). It is thought that pregnancy, childbirth, and 
abortion each predispose women to C. sordellii infections by allowing the ascending 
infection of necrotic decidual tissue upon dilatation of the cervix (21). Interestingly, the 
majority of cases associated with medical abortion (7 of 8 reported cases) involved the 
intravaginal application of misoprostol, the synthetic prostaglandin (PG)E2 analogue that is 
used in conjunction with the orally administered anti-progesterone drug mifepristone (RU-
486) (2, 21), suggesting that one additional risk factor for C. sordellii uterine infection might 
be the suppression of FRT innate immunity by high local concentrations of a PGE2-like 
compound (7). However, this has not been definitively established.  
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Macrophage Receptors Involved in Phagocytosis 
The process of phagocytosis consists of three main steps: binding of a ligand (e.g. 
pathogen), cell activation and membrane motility, and entry into the cytoplasm (19). The 
initial means of binding is done through receptors located on the cell surface. These receptors 
are generally divided into the two categories of opsonic (e.g. FcγR, complement receptors, 
and CD14) or non-opsonic (e.g. mannose, scavenger, and complement receptor 3, dectin 1) 
(19).  
One class of non-opsonic phagocytic receptors that is of particular importance is the 
SR. The SRs are transmembrane proteins that can be divided into at least eight different 
subclasses (A-H) based on their tertiary structure (41, 42). The CASRs are of special interest 
because they are widely expressed on macrophages (32). These receptors have previously 
been shown to bind Gram-positive bacteria through the recognition of lipoteichoic acid (18, 
22) and may therefore play a key role in the phagocytosis of C. sordellii. In 2003, Melville 
and O’Brien demonstrated the importance of the CASR, and to a lesser degree the mannose 
receptor, in the binding and phagocytosis of C. perfringens (35).  With the use of the CASR 
inhibitor, fucoidan, they found an 80% reduction in bacterial cell association. Reductions of 
50% and 20% were also observed with the mannose inhibitors methyl-α-D-mannopyranoside 
and mannan, respectively (35).   
The CASRs are subdivided even further into five different groups: SR-AI, SR-AII, 
SR-AIII, macrophage receptor with collagenous structure (MARCO), and scavenger receptor 
with C-type lectin (SRCL) (32). The SR-AI, II, and III isoforms are derived from the same 
gene on chromosome 8 with alternative splicing producing the different proteins (32). A 
separate gene encodes the MARCO receptor and is located on chromosome 2 (32).  SRCL is 
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an endothelial CASR that has also been identified on alveolar macrophages (42). An 
additional CASR , SCARA5, recently characterized in murine epithelial cells associated with 
mucosal surfaces, was found to have similar binding properties as other CASRs (27). 
Functional roles in microbial clearance for either SRCL or SCARA5 receptors have not been 
identified for human phagocytes.   
Extensive data support a functional role of the MARCO receptor in macrophage 
phagocytosis outside of the FRT. The cell surface expression and mRNA levels of MARCO 
are enhanced upon bacterial binding and provide evidence for its significance in bacterial 
clearance (32). In addition, studies using alveolar macrophages found MARCO to be the 
major receptor for unopsonized bacteria (10, 36). Thus, it is probable that human DMs are 
using the CASRs, possibly including MARCO receptors, to bind and engulf C. sordellii. 
However, a lack of information exists showing the presence or absence of CASRs on DMs.   
A study by Laskarin et al. suggested the mannose receptor is a functional receptor on 
decidual mononuclear cells (29). The exact role of the mannose receptor in phagocytosis is 
uncertain with conflicting biochemical and genetic studies (19). Due to its decreased 
expression during inflammation (16), it has been suggested the mannose receptor may be 
more important for tissue homeostasis than for host defense (19). However, taking into 
consideration this information and the previously mentioned studies by O’Brien and 
Melville, this receptor was also tested to determine its importance in the binding and 
phagocytosis of C. sordellii.   
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Broader Relevance to Human Health 
Although C. sordellii infections are uncommon, other bacterial infections that occur 
more commonly within the FRT cause an array of frequently encountered complications.  
These complications occur primarily due to the inability of our innate immune system to fend 
off the infection.  This can result in many afflictions, including ectopic pregnancy, 
miscarriage, stillbirth, and congenital infections, which can result in chronic disability (e.g. 
infertility) and death.  When a bacterial infection reaches the upper FRT, it can cause pelvic 
inflammatory disease. Twenty percent of women who develop pelvic inflammatory disease 
become infertile (50).  These bacterial infections can also cause endometritis, 
chorioamnionitis, and pre-term births, resulting in approximately 70% of perinatal deaths 
(49).  Determining the mechanism behind C. sordellii infections and their relationship with 
prostaglandins will expand not only our knowledge in bacterial pathogenesis, but also our 
understanding of the immunology of the FRT in general.   
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Chapter 3: Materials and Methods 
 
Animals 
Six 8-week-old, female SR-AI/II/II deficient (SR-AI/II
-/-
) mice on a 129/SvJ strain 
background were originally provided as a generous gift of Dr. Willem J. S. de Villiers 
(University of Kentucky Medical Center, Lexington, KY, USA) and were subsequently bred 
at the University of Michigan. Age- and sex-matched 129/SvJ wild-type (WT) mice were 
purchased from Jackson Laboratory (Bar Harbor, ME). Six 8-wk-old, female mice 
genetically deficient in MARCO (MARCO
-/-
) on a BALB/c background were bred as 
previously published (9) and utilized with the generous permission of Dr. Karl Tryggvason 
(Karolinska Institute, Stockholm, Sweden), who initially provided the MARCO
-/-
 mice. The 
genotypes of mouse strains were confirmed by tail-snip DNA PCR analyses performed by 
Transnetyx (Cordova, TN). Age- and sex-matched BALB/c WT mice were purchased from 
Jackson Laboratory. Animals were treated according
 
to National Institutes of Health 
guidelines for the use of experimental
 
animals with the approval of the University of 
Michigan Committee
 
for the Use and Care of Animals. 
 
Bacteria 
C. sordellii strain ATCC9714 was obtained from the American Type Culture 
Collection (Manassas, VA) and grown anaerobically in broth culture overnight at 37
o
C in 
reinforced clostridial medium (RCM) (BD Biosciences). Estimates of bacterial 
concentrations were derived from the optical density (OD) of bacterial cultures at 600 nm 
(OD600) and a previously-determined standard curve of colony forming units (CFU) vs. 
OD600. Estimated bacterial concentrations were confirmed by serial 10-fold dilutions on solid 
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agar composed of RCM containing 1.5% (w/w) agar, incubated anaerobically. For 
phagocytosis experiments (below), heat-killed C. sordellii were prepared by heating to 121
°
C 
for 30 min. 
 
Reagents 
RPMI 1640, penicillin/streptomycin/amphotericin
 
B solution, TRIzol®, and 
acetylated low-density lipoprotein (AcLDL) were from Life Technologies-Invitrogen 
(Carlsbad, CA). Fetal bovine serum (FBS) and charcoal-stripped
 
FBS were from HyClone 
Laboratories (Waltham, MA). RCM, mouse anti-human CD14 IgG (clone MPHIP9), and 
monoclonal antibody CD11b (clone D12) were from BD Biosciences (San Jose, California). 
Cytochalasin
 
D, hyaluronidase, deoxyribonuclease, Percoll®, fucoidan, polyinosinic acid 
(Poly(I)), polycytidylic acid (poly(C)), dextran sulfate, chondroitin sulfate, mannan, 
fluorescein isothiocyanate (FITC), and trypan blue were from Sigma-Aldrich (St. Louis, 
MO).
 
Magnetic MACS® CD14 microbeads (human) were from Miltenyi Biotec (Auburn, 
CA). Recombinant mouse soluble MARCO (sMARCO) and monoclonal anti-human CD163 
(clone 215927) were purchased from R&D Systems (Minneapolis, MN). F4/80 (clone 
6A545) monoclonal IgG was from Santa Cruz Biotechnology (Santa Cruz, California). 
Mouse monoclonal CD36 IgG (clone FA6-152) was purchased from Abcam (Cambridge, 
MA).  
 
Human Subjects  
Following appropriate informed consent, human decidual tissue was obtained from 
healthy adult women aged 18-44 years undergoing elective surgical termination of pregnancy 
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during the first trimester. This study was reviewed and approved by the University of 
Michigan Institutional Review Board. 
 
Decidual Macrophage Isolation 
This procedure was adapted from a previously described protocol (47). First trimester 
decidual tissue was collected from surgical abortions under sterile conditions. The tissue was 
weighed, minced into small pieces, and the tissue digested with a solution containing 1 
mg/ml collagenase (Sigma), 1 mg/ml hyaluronidase (Sigma), and 150 μg/ml DNase (Sigma). 
Ten mls of digestion solution were used per gram of tissue. The samples were digested on a 
shaker at 37
°
C for 60 minutes.  The sample was washed using RPMI medium 1640 
containing L-glutamine (Gibco) and 1% antibiotic-antimycotic (Gibco) and centrifuged at 
365 x g RCF at 4
°C for 10 min. This was followed with a series of 280 μm, 200 μm, and 100 
μm nylon mesh filtrations to eliminate any remaining particulates. The cells were washed as 
previously described and the filtrate was suspended in 25% Percoll (Sigma) in RPMI (same 
as above) and overlaid onto 50% Percoll, with 2 mls PBS layered above the 25% Percoll.  
Decidual cells are recovered from the 25/50 interface following a 4
°
C centrifugation for 45 
minutes at 365 x g RCF. These cells were washed as above, followed by a red blood cell lysis 
using NH4Cl/Tris-HCl. After two washes with RPMI medium 1640 containing L-glutamine 
(Gibco) and 1% antibiotic-antimycotic (Gibco), the cells were then passed through a 30 μm 
falcon filter (BD Biosciences) to remove any cellular clumps and/or debris.  
Using typical macrophage markers, including CD14
+ 
(Becton Dickinson), F4/80
+ 
(Santa Cruz), and CD11b
+ 
(Becton Dickinson), we were able to verify that macrophages 
make up ~10% of human decidual tissue (results not shown).  These results are in accordance 
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with previous findings (44).  The isolated cells underwent a positive selection for 
macrophages by passing through two successive large cell columns (Miltenyi Biotec) using 
MACS® CD14 microbeads (Miltenyi Biotec).  Flow cytometry was used to confirm the 
purity of our isolation, with > 94% of cells CD14
+
 (results not shown).   
 
Resident Peritoneal Macrophage Isolation 
Resident peritoneal macrophages from mice were obtained
 
via peritoneal lavage as 
previously
 
described (12, 37). A red blood cell lysis was performed and cells were suspended 
in RPMI 1640 containing 10% FBS and 1% penicillin/streptomycin/amphotericin. Cells were 
plated in 384-well tissue culture-treated plates (Costar) at 2 x 10
5
 cells/well and incubated 
overnight (37°C with
 
5% CO2). The following day cells were washed two times
 
with warm 
RPMI to remove nonadherent cells.
  
 
RNA Extraction, cDNA Synthesis 
TRIzol® (Invitrogen) was added to the CD14+ cells to perform an RNA extraction.  
After complete dissociation, chloroform (Sigma) was added to a final concentration of 200 
µl/ml Trizol®.  Samples were centrifuged at 16,000 x g RCF for 15 min at 4
°
C, the aqueous 
phase was taken off, and an equal volume of isopropanol was added.  After 20 minutes 
incubation at room temperature, samples were centrifuged at 16,000 x g RCF for 15 min at 
4
°
C.  The pellet was suspended in 500 µl 80% ethanol and centrifuged at 16,000 x g RCF for 
15 min at 4
°
C.  DEPC water was added to the pellet, and RNA concentration was determined 
via nanodrop.  1 µg RNA was transcribed into cDNA using the Transcriptor First Strand 
cDNA Synthesis Kit (Roche) per manufacturer’s instructions.  Samples were run on a 
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Mastercycler epgradient S (Invitrogen) with the following conditions; 65
°
C for 10 min, 50
°
C 
for 60 min, and 85
°
C for 5 min.    
 
Semiquantitative Real-Time PCR 
Primers and probes were designed using the Universal ProbeLibrary Assay Design 
Center at www.roche-applied-science.com.  All primers were from Integrated DNA 
Technologies (Coralville, IA), and all probes were from Roche (Table 1).  Universal 
ProbeLibrary Reference Gene Assays for GAPDH were used for human and mouse (Roche).  
To prepare the assay, 2 µl cDNA were used according to manufacturer’s instructions and run 
on the LightCycler 480 (Roche) with the following conditions: 95
°
C 10 min (preincubation), 
95
°
C 10 sec, 60
°
C 30 sec, 72
°
C 1 sec (amplification, 45 cycles), 95
°
C 10 sec, 50
°
C 30 sec, 
70
°
C 5 min (melting curve), 40
°
C 30 sec (cooling).  Analysis was performed using Roche 
software; all samples were referenced to the expression of the housekeeping gene GAPDH.   
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Table 1: Primers and Probes used for PCR amplification of SRs. 
Gene Forward Primer Reverse Primer UPL Probe # 
MSR1 tcccactggagaaagtggtc ctccccgatcacctttaagac 85 
MARCO tgctgggttactccaaagga cagccagatctgcccagt 24 
SCARA5 tgggcatcttcatcttagca cattcagccggttcacatt 24 
CD36 tggaacagaggctgacaactt ttgattttgatagatatgggatgc 76 
CD163 tggggaaagcataactgtga gctcagatctgctccctttg 67 
COLEC12 cagagcgtgaaaatgaatgg tgtccagctttccaatttttg 42 
Msr1 (M. musculus) ctttaccagcaatgacaaaagaga atttcacggattctgaactgc 89 
Marco (M. musculus) ggcaccaagggagacaaa tcccttcatgcccatgtc 97 
 
Phagocytosis Assays 
CD14
+
 cells were cultured overnight in 384-well tissue culture-treated plates (Costar) 
with 2 x 10
5
 cells/well at 37
°
C. The cells were treated with specific compounds of interest 
and incubated for 30 min at 37
°
C.  Heat-inactivated C. sordellii were surfaced-labeled with 
FITC per previously published protocol (11). FITC-labeled C. sordellii (
FITC
C. sordellii) were 
applied at a multiplicity of infection (MOI) of 300 bacteria:1 cell and incubated for 3 hrs at 
37
°
C. Trypan blue (250 μg/ml; Molecular Probes) was added to quench extracellular bacteria 
including those bound to the cell that had not been internalized. Phagocytosis was quantified 
according to a previously published method (7) by determining the fluorescence of 
intracellular bacteria within DMs using a microplate fluorometer (485ex/535em, 
SPECTRAMax GEMINI EM; Molecular Devices, Sunnyvale, CA). The data received are 
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expressed in arbitrary relative fluorescence units (RFU), which were converted into a 
phagocytic index (PI).  The PI represents only bacteria that were intracellular (RFUi) and is 
calculated by subtracting the extracellular bacteria (RFUex) from the total fluorescence of the 
well (RFUtotal).  The RFUex was determined by treating 3-4 wells with a phagocytic inhibitor, 
cytochalasin D (5 µl/ml; EMD chemicals), for 30 min prior to exposure with C. sordellii.  
The fluorescence from these wells represents unquenched extracellular bacteria and was 
subtracted from the RFUtotal.  Therefore, the PI = RFUi = RFUtotal - RFUex (6). Control wells 
containing only cells and media were used to determine the amount of background 
fluorescence; this RFU value was subtracted from all other values to compensate for this 
fluorescence. 
Select compounds tested included the nonspecific CASR blocking agents fucoidan, 
poly(I), and dextran sulfate; the negative control compounds chondroitin sulfate and poly(C); 
the mannose receptor blocker mannan; sMARCO; and the SR-AI/II blocking agent AcLDL. 
CBSR-blocking antibodies used included the mouse monoclonal anti-human CD163 and 
CD36 IgGs (33). Phagocytosis assays with mouse macrophages were similarly performed; 
however, a MOI of 150:1 was used. In addition, for assays comparing wild-type DM cells 
with either MARCO
-/-
 or SR-AI/II
-/-
, the results were normalized to total intracellular lactate 
dehydrogenase activity levels in control wells without bacteria to account for potential 
differences in cell number or adherence to tissue culture plates (13). Lactate dehydrogenase 
activity was determined by a commercially available assay according to the manufacturer’s 
instructions (Roche). 
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Intrauterine Infections 
C. sordellii was cultured anaerobically (24 hr, 37
°
C) in 10 ml RCM broth (BD 
Biosciences). The bacteria were then centrifuged (650 x g RCF x 10 min) and the pellet 
washed three times with sterile phosphate buffered saline (PBS) and suspended in 1 ml total 
volume of PBS. Dilutions were made in PBS to allow the inoculation of ~1 x 10
4
 CFU 
directly into one horn of the mouse uterus, according to our previously published protocol 
(7), in a total volume of 35 l. The actual inoculum was determined by plating serial 10-fold 
dilutions of the PBS suspension onto RCM agar and counting individual colonies the next 
day. For survival experiments, the mortality from infection was monitored for eight days 
following inoculation.  
 
Bacterial Clearance and Dissemination Studies 
For studies of bacterial clearance and dissemination, mice were infected intrauterine 
as above with 1 x 10
3
-10
4
 CFU C. sordellii. The uterus and spleen were harvested 24 hrs 
after infection and mechanically homogenized in 1 ml of sterile PBS. Then, 50 μl of 
homogenized sample was cultured anaerobically on RCM agar, and colonies were 
enumerated after 24 hrs. Results were expressed as CFU per ml of homogenate.  
 
Statistical Analyses 
Mean values were compared using a one-way analysis of variance (ANOVA) 
followed by a Bonferroni correction or a paired Student t-test as indicated. Differences were 
considered significant if P  0.05. Comparison of survival curves for mice infected with C. 
sordellii was performed using a Mantel-Cox log-rank test. Experiments were performed on at 
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least three separate occasions
 
unless otherwise specified. Unless otherwise noted, data are 
presented as mean values ± standard error of the mean (SEM). 
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Chapter 4: Results 
Fucoidan inhibits the phagocytosis of C. sordellii by human DMs 
Because C. perfringens was reported to be phagocytosed predominantly through 
CASRs in non-reproductive tract macrophages (35), we hypothesized that human DMs 
utilized CASRs in phagocytosing C. sordellii. To test this, DMs were pretreated with 
fucoidan, an antagonist of CASRs that is not selective for the unique CASR subtypes (15). A 
30-min preincubation with fucoidan at 100 and 500 µg/ml dose-dependently and significantly 
inhibited the phagocytosis of 
FITC
C. sordellii by 75.8 + 4.9% and 96.0 + 2.0%, respectively 
(Fig. 1A). Pilot experiments demonstrated that maximal inhibition was obtained using 500 
µg/ml of fucoidan (data not shown), so this concentration was used as a positive, 
comparative control in other phagocytosis assays.  
 
Human DMs express CASR receptors 
Having established a possible role for CASRs in immune recognition of C. sordellii, 
experiments were conducted to determine their expression levels in DMs using semi-
quantitative real-time PCR. Although a functional mannose receptor has been identified on 
human DMs (29), to our knowledge other phagocytic receptors, including the CASRs and 
CBSRs, have not been well characterized. Thus, mRNA was isolated from unstimulated 
human DMs, and real-time PCR was performed for the CASR receptors SR-AI/II, MARCO, 
SRCL, and SCARA-5. SRCL is an endothelial CASR that has also been identified on 
alveolar macrophages (42). SCARA5 was recently characterized in murine epithelial cells 
and was found to have similar binding properties to other CASR receptors (27). However, 
18 
 
 
 
functional roles in microbial clearance for either SRCL or SCARA5 receptors have not been 
identified for human phagocytes. The expression of two CBSRs implicated in binding 
bacteria, CD36 and CD163, was also evaluated (14, 20). These experiments revealed 
expression of multiple SRs (Fig. 1B). Of the CASRs, the expression of SR-AI/II was 
greatest, being significantly higher than SCARA-5, which was only minimally expressed. 
SR-AI/II transcripts were not significantly greater than mRNA levels of MARCO. We also 
found a significantly higher expression of CD163, when compared with CD36.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Evidence for functional scavenger receptors in human DMs. A, Human DMs 
were pretreated for 30 min with the scavenger receptor blocker fucoidan (in µg/ml) and 
phagocytosis of 
FITC
C. sordellii quantified as detailed in Materials and Methods. Data are 
representative from three independent experiments performed in octuplet with similar results. 
Results are expressed as a percentage of phagocytosis relative to untreated cells. ***, P < 
0.001 vs. untreated cells by ANOVA. B, Semi-quantitative real-time PCR performed to 
measure expression levels of scavenger receptors in human DMs, relative to GAPDH, 
described in Materials and Methods. Data points represent the mean result from 12 separate 
individuals performed in triplicate. **, P < 0.01; ***, P < 0.001 comparing CD163 against 
each of the other receptors (ANOVA). 
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Multiple pharmacological antagonists of CASRs impair phagocytosis of C. sordellii by 
human DMs 
 
The above data suggested that human DMs express functional CASRs, but these 
experiments were limited by the use of a single, nonselective CASR antagonist, fucoidan. 
Thus, phagocytosis assays were performed using additional, standard, nonselective CASR 
blocking agents. When cells were pre-incubated with dextran sulfate (100 µg/ml), there was 
an 87.3 + 6.1% decrease in phagocytic ability, while the negative control (but structurally 
similar) agent chondroitan sulfate (100 µg/ml) had no effect (Fig. 2A). Another classical 
CASR antagonist, Poly(I), suppressed phagocytosis by 48.5 + 6.2% compared to vehicle 
treatment, while the negative control compound Poly(C), had no effect (Fig. 2B). The 
generalizability of these results for other types of macrophages was tested by conducting 
experiments using resident peritoneal macrophages isolated from female Wistar rats, which 
yielded similar results (data not shown). While these observations further implicated CASRs 
in the phagocytosis of C. sordellii by human DMs, they did not differentiate among the 
various subtypes. 
A previous study by O’Brien and Melville identified a minor role for the mannose 
receptor in the macrophage phagocytosis of C. perfringens (35). However, we found no role 
for this receptor in the phagocytosis of C. sordellii when human DMs were pre-incubated (30 
min) with the antagonist mannan (100 µg/ml) (Fig. 2C). We also failed to identify a role for 
mannose receptors in C. sordellii phagocytosis using resident rat peritoneal macrophages 
(data not shown).  
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Figure 2. Non-selective class A scavenger blockers inhibit phagocytosis of C. sordellii, 
while mannose receptor blockers have no effect. A, human DMs were pretreated for 30 
min with the CASR blocking agent dextran sulfate (DxSO4, 100 µg/ml) or the negative 
control agent chondroitan sulfate (ChdSO4, 100 µg/ml) and the phagocytosis of 
FITC
C. 
sordellii was quantified by fluorometry after 180 min as detailed in Materials and Methods. 
B, human DMs were pretreated for 30 min with the CASR blocking agent Poly(I) (200 
µg/ml) or the negative control Poly(C) (200 µg/ml) and the phagocytosis of 
FITC
C. sordellii 
was quantified by fluorometry after 180 min as detailed in Materials and Methods. C, human 
DMs were pretreated with fucoidan (500 g/ml) or the mannose receptor blocker, mannan 
(100 µg/ml ) for 30 min and the phagocytosis of 
FITC
C. sordellii was quantified by 
fluorometry after 180 min as detailed in Materials and Methods. Data are representative from 
three independent experiments performed in octuplet with similar results. Results are 
expressed as a percentage of relative to untreated cells. ***, P < 0.001 vs. control as 
determined by ANOVA.  
 
MARCO is the predominant phagocytic receptor for C. sordellii by human DMs  
To determine which of the predominant CASRs expressed by human DMs (SR-AI/II 
and MARCO) are primarily responsible for internalizing C. sordellii, a previously published 
pharmacological approach to selectively antagonize these receptors was employed (39). Cells 
were preincubated (30 min) either with recombinant, mouse sMARCO or with the SR-AI/II-
selective agent AcLDL (39). AcLDL had no effect on C. sordellii phagocytosis, while 
sMARCO inhibited phagocytosis by 79.5 + 2.1% (Fig. 3A). These data implicated MARCO 
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as the predominant phagocytic receptor for C. sordellii on human DMs. Because DMs 
express CBSRs (Fig. 1B) and macrophage CBSRs have been shown to bind and phagocytose 
bacteria (14, 20, 45), we preincubated DMs with monoclonal antibodies against human 
CD163 and CD36 (50 µg/ml) before measuring phagocytosis. Consistently, a small but 
statistically significant inhibitory effect (~30% inhibition) on phagocytosis was observed 
when cells were treated with anti-CD36 treatment, whereas the CD163 antibody had no 
effect (Fig. 3B). Thus, CD36 appears to play a minor role in phagocytosing C. sordellii.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Soluble MARCO and anti-CD36 IgG prevent the phagocytosis of C. sordellii 
by human DMs.  A, Human DMs were pretreated with sMARCO (100 µg/ml) or the SR-
AI/II-binding agent acetylated low density lipoprotein (AcLDL; 100 µg/ml) for 30 min and 
the phagocytosis of 
FITC
C. sordellii was quantified by fluorometry after 180 min as detailed 
in Materials and Methods. B, Human DMs were pretreated with mouse anti-human 
monoclonal IgG directed against CD36 or CD163 (or an isotype control) at 50 µg/ml for 30 
min and the phagocytosis of 
FITC
C. sordellii was quantified by fluorometry after 180 min as 
detailed in Materials and Methods. Fucoidan pretreatment for 30 min at 500 µg/ml used as 
positive control for each. Data are representative from three independent experiments 
performed in octuplet with similar results.  Results are expressed as a percentage of relative 
to untreated cells.  **, P < 0.01 and ***, P < 0.001 vs. untreated cells.  
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MARCO but not SR-AI/II receptors are critical for mouse macrophage phagocytosis of C. 
sordellii  
 
The above experiments were limited by their pharmacological approach. The 
availability of CASR-deficient mice allowed an alternative approach to test the importance of 
these receptors in the phagocytosis of C. sordellii. Resident peritoneal macrophages obtained 
from SR-AI/II
-/-
 mice, MARCO
-/-
 mice, or respective WT animals were challenged with 
FITC
C. sordellii and their relative phagocytic capacity was determined. We observed that 
macrophages from SR-AI/II
-/-
 mice exhibited ~3.18 ± 0.75-fold greater phagocytosis of C. 
sordellii compared to WT cells (P<0.05; Fig. 4A). This phagocytic ability was inhibited > 
90% using sMARCO (data not shown). Real time PCR was performed to determine whether 
there were compensatory changes in MARCO expression in the SR-AI/II
-/-
 macrophages 
correlating with their enhanced phagocytic capacity. As shown (Fig. 4B), MARCO mRNA 
levels were, on average, 5.3-fold higher in SR-AI/II
-/-
 macrophages than in WT cells 
(P<0.05).  
These data suggest that in the absence of the SR-AI/II receptors, MARCO was able to 
internalize C. sordellii. To test this, we compared phagocytosis of unopsonized 
FITC
C. 
sordellii using WT and MARCO
-/-
 peritoneal macrophages. As shown (Fig. 4A), 
phagocytosis was significantly lower in macrophages lacking MARCO. Real-time PCR (Fig. 
4B) did not detect any significant compensatory increase in mRNA expression of SRA-I/II. 
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Figure 4.  MARCO is more important than SR-AI/II in the phagocytosis of C. sordellii. 
A, Left panel, peritoneal macrophages from either wild-type (WT) BALB/c mice or 
MARCO
-/- 
mice were allowed to phagocytose 
FITC
C. sordellii for 3 hr. Right panel, peritoneal 
macrophages from either wild-type (WT) 129/SvJ mice or SR-AI/II
-/- 
mice were allowed to 
phagocytose 
FITC
C. sordellii for 3 hr. The phagocytosis of 
FITC
C. sordellii was quantified by 
fluorometry as detailed in Materials and Methods. KO, knockout cells. *P <0.05 vs. WT by 
Student t-test. Results are a mean ± SEM of 3-5 independent experiments performed in 
octuplet. B, mRNA expression of SR-AI/II or MARCO in mouse peritoneal macrophages 
was determined by semi-quantitative real-time PCR as detailed in Materials and Methods. 
Left panel, mRNA levels were compared between WT BALB/c peritoneal macrophages 
(black bars) or MARCO
-/-
 cells (gray bars). Right panel, mRNA levels were compared 
between WT 129/SvJ peritoneal macrophages (black bars) or SR-AI/II
-/-
 cells (striped bars). 
Data are normalized to GAPDH expression and represent the mean ± SEM of 8 mouse 
samples per assay. *P < 0.05 vs. WT cells by Student t-test.   
 
MARCO deficient mice have enhanced susceptibility to C. sordellii infection 
Because the above in vitro experiments with mouse PMs and human DMs suggested 
that MARCO is an important immunosurveillance receptor used by FRT macrophages to 
defend the host against C. sordellii, we tested its importance, in this context, in vivo. Wild-
type or MARCO
-/-
 mice were inoculated intrauterine with the virulent C. sordellii strain 
ATCC9714. Using an inoculum of 1 x 10
4
 CFU per mouse, only 15% of infected WT 
BALB/c mice died as a result of infection (Fig. 5A). In contrast, MARCO
-/-
 mice were 
significantly more susceptible to death from infection, with a 3-fold higher mortality of 45% 
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by 7 days post-infection (Fig. 5A, n = 20 mice per group, P = 0.04 by Mantel-Cox log-rank 
test). In contrast, SR-AI/II
-/-
 mice were not more susceptible to death from intrauterine C. 
sordellii infection compared to WT 129/SvJ mice (Fig. 5C). 
 
MARCO is important for clearance of bacteria from the infected uterus 
We questioned whether the increased mortality observed in MARCO
-/-
 mice 
correlated with an impaired capacity to eliminate bacteria from the infected uterus. To 
address this question, mice were infected intrauterine with C. sordellii and the organ bacterial 
load was determined by anaerobically culturing tissue homogenates harvested at 24 hr post 
infection. As illustrated (Fig. 5B), there was a significantly greater bacterial load in the 
uterus 24 hr after infection in the MARCO
-/-
 mice compared to WT animals. To address 
dissemination of infection from the uterus, spleens were harvested 24 hr following 
inoculation and bacterial burdens were determined for both WT and MARCO
-/-
 mice. 
Although a greater number of MARCO-deficient mice had evidence of splenic dissemination 
compared to wild type mice (3 of 10 MARCO-deficient mice vs. 1 of 10 wild type mice), 
neither this outcome nor the mean bacterial loads per spleen were significantly different 
between the two groups (data not shown). We have not detected differences in local 
clearance of C. sordellii from the uterus or dissemination to the spleen between WT or SR-
AI/II
-/-
 mice (data not shown). 
 
 
 
 
 
25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. MARCO is important to host defense against intrauterine C. sordellii 
infection. A, Wild-type (WT) or MARCO knockout (KO) mice (n=20 per group) were 
infected by intrauterine injection with C. sordellii ATCC9714 (1x10
4
 CFU per mouse) and 
survival was recorded. *P < 0.05 vs. WT survival. B, The bacterial load of C. sordellii was 
determined in uterine homogenates 24 hrs after infection as described in the Materials and 
Methods. Shown are the mean ± SEM of 5 mice per group from one of two independent 
experiments showing similar results. *P < 0.05 vs. WT. CFU, colony-forming units. C, 
Wild-type (WT) or SR-A knockout (KO) mice (n=10 per group) were infected by 
intrauterine injection with C. sordellii ATCC9714 (1x10
4
 CFU per mouse) and survival was 
recorded. Differences were not significant. 
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Chapter 5: Discussion 
These studies newly define a potentially important role for MARCO receptors in the 
innate host defense against invasive C. sordellii infections of the FRT. Infections caused by 
toxigenic clostridia are emerging as important challenges to human health. While the 
problem of clostridial infections is growing, there has been little research into the 
mechanisms detailing how the innate immune system recognizes and attempts to eliminate 
these potential pathogens. The increase in published reports of highly lethal C. sordellii 
gynecological infections in women of childbearing age (2, 24, 25) prompted further study of 
the pathogenesis of C. sordellii infections. To our knowledge, these studies show for the first 
time the receptors through which human macrophages internalize these toxigenic bacteria.  
Macrophages are key sentinels of innate immunity that respond to microbial invaders 
by elaborating immunoregulatory mediators (cytokines, chemokines, and lipids), 
phagocytosing and killing potential pathogens, and presenting antigens to cells of the 
adaptive immune system. Recently, the TLRs 2 and 6 were found to participate in the 
immune response of macrophages to C. sordellii, through the activation of the transcription 
factor NFB (1). However, these studies did not address how macrophages phagocytose this 
bacterium.  
Previous investigations with the related pathogen, C. perfringens, revealed that 
CASRs, and to a lesser extent the mannose receptor, were involved in the macrophage 
phagocytosis of this pathogen (35). Phagocytosis of C. perfringens was impaired in those 
studies using the non-selective CASR blocking agent fucoidan (35). However, that study did 
not establish the relative roles played by individual CASRs in C. perfringens uptake. 
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Although the authors used Chinese hamster ovarian cells transfected with the mouse SR-AI 
receptor to demonstrate binding of C. perfringens to SR-AI, the capacity of SR-AI to mediate 
the internalization of this bacterium was not reported (35).  
Based largely on the findings of these important studies of C. perfringens, we 
questioned whether CASRs would also be important for the phagocytosis of C. sordellii by 
human macrophages. Similar to the approach of O’Brien and Melville (35), we incubated 
DMs with fucoidan and noted that this broad inhibitor of CASR phagocytosis was a potent 
blocker of C. sordellii internalization. We then used mRNA expression as a surrogate marker 
for phagocytic receptor expression by DMs. Using a real-time PCR based approach, we 
identified transcription of the MSR1 and the MARCO genes, encoding SR-AI/II and 
MARCO, respectively. These studies newly documented the expression of SRCL on DMs, a 
receptor expressed primarily on non-hematopoeitic cells (e.g., endothelial cells) (4, 42). We 
also investigated whether SCARA-5 was expressed by human DMs, as this receptor has not 
been well characterized in human cells and tissues (27). However, we did not observe 
significant expression of this receptor. 
To confirm the results obtained with fucoidan, we utilized pairs of non-selective 
CASR blocking agents and structurally matched, negative control compounds that do not 
bind to CASRs (e.g., Poly(I)-Poly(C) and dextran sulfate-chondroitan sulfate). Indeed, 
phagocytosis was inhibited by both dextran sulfate and poly(I) but not by the negative control 
agents chondroitan sulfate or poly(C).  
A study by Laskarin et al. suggested the mannose receptor is a functional receptor on 
decidual mononuclear cells (29). The exact role of the mannose receptor in phagocytosis is 
uncertain with conflicting biochemical and genetic studies (19). Due to its decreased 
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expression during inflammation (16) it has been suggested the mannose receptor may be 
more important for tissue homeostasis than for host defense (19). However, taking into 
consideration this information and the previously mentioned studies by O’Brien and 
Melville, this receptor was also tested to determine its importance in the binding and 
phagocytosis of C. sordellii. We found no major role for the mannose receptor in our 
experimental design. 
TLR2 has been shown to play a role in bacterial uptake by both macrophages (46) 
and mouse trophoblast giant cells (48). Because of this potential role for TLRs in C. sordellii 
infections, we also performed phagocytosis assays with human DMs using a TLR2-blocking 
IgG. When pretreating the cells at 50 or 100 µg/ml, we found no inhibition of phagocytosis 
when compared to an isotype control IgG (data not shown). This suggests TLR2 is not 
involved in the internalization of C. sordellii.  
Given the potentially critical role for CASRs in the macrophage phagocytosis of C. 
sordellii, we sought to decipher which specific subtypes were most important. There is 
precedent to suggest that different pathogens may bind unique CASRs with varying 
efficiency (38, 39). We initially incubated human DMs with either AcLDL, a specific 
antagonist of SR-AI/II receptors (39), or sMARCO, a specific inhibitor of MARCO-
dependent phagocytosis (39, 41). These studies found that phagocytosis could be potently 
blocked by sMARCO but not by AcLDL, suggesting that MARCO is the more critical 
receptor for the phagocytosis of C. sordellii.  
These pharmacological results were confirmed using receptor-deficient mice. We 
were surprised to observe a significantly greater phagocytic capacity in SR-AI/II
-/-
 
macrophages compared with WT cells (Fig. 4) and speculated that this might be due to 
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enhanced MARCO expression, which has been observed in SR-AI/II
-/-
 mice, though on a 
different genetic background (28). The fact that sMARCO inhibited the phagocytic capacity 
of the SR-AI/II
-/-
 macrophages suggested this might be the case (data not shown). Indeed, 
mRNA transcript levels for MARCO were significantly greater in SR-AI/II
-/-
 macrophages 
than WT macrophages (Fig. 4), providing more evidence that MARCO expression is up-
regulated in mouse cells lacking SR-AI/II. These data were limited by the fact that mRNA 
transcripts were quantified, not surface expressed protein levels. However, a previous study 
of SR-AI/II
-/-
 peritoneal macrophages (on a BALB/c background) showed higher surface 
expression of MARCO using an anti-MARCO antibody (28).  
While our in vivo data provide novel and correlative support for our in vitro results 
that MARCO is an important component of the innate defense against C. sordellii infections, 
it does not prove that decidual macrophages are the only cells involved in such uterine 
infections. To address this, we used the human uterine epithelial cell (UEC) line, RL95-2 
(purchased from the ATCC), in phagocytosis assays in the same manner as with decidual 
macrophages to determine if they were able to phagocytose or otherwise internalize C. 
sordellii. We did not observe any significant intracellular fluorescence in these UECs (data 
not shown), indicating these cells do not avidly take up C. sordellii in vitro or in vivo. 
Notably, MARCO
-/-
 peritoneal macrophages demonstrated an impaired capacity to 
phagocytose C. sordellii. These data supported our pharmacological results in the human 
cell. What is more, we observed, for the first time, a functional role for MARCO in immune 
defense against clostridia in vivo. Importantly, mice lacking functional MARCO receptors 
demonstrated increased susceptibility to lethal infection by C. sordellii and impaired 
clearance of these bacteria from the uterus (Fig. 5A and B). As expected, we did not see any 
30 
 
 
 
enhanced susceptibility to infection in SR-AI/II null mice (Fig. 5C). We have also not 
observed differences in bacterial clearance from the uterus comparing WT and SR-AI/II null 
mice (data not shown).  
Our data are in accord with previously published studies of the role of MARCO in 
immune defense against bacterial pathogens of the lung (8). In a murine model of pneumonia 
caused by the Gram-positive pathogen Streptococcus pneumoniae, MARCO-deficient mice 
displayed an impaired ability to clear bacteria from the lungs and significantly diminished 
survival (8). Our findings imply that genetic differences in MARCO expression or function 
might influence the risk of C. sordellii or other clostridial infections.  
There are several limitations in our work. The bacteria used in our studies of 
phagocytosis were heat-killed, FITC-labeled C. sordellii, which would not be found in 
nature. Thus, these results may be different using live bacteria. In addition, the bacteria used 
were in a vegetative (non-sporulating) form, which models active invasion with replicating 
bacteria. However, future studies of the phagocytosis of spore forms will be of interest as 
well. Our study was also limited by the fact that we did not differentiate between the mRNA 
expression of SR-AI and SR-AII. These receptors are transcribed from the same gene and 
differ as a result of alternative mRNA splicing (30). An additional caveat is that the rodent 
cells used for these studies were peritoneal macrophages, which may differ significantly from 
reproductive tract cells. Thus, direct comparisons with human DMs are difficult.   
These studies newly described expression of SRCL by human DMs. This receptor, to 
our knowledge, has not been shown to be a functional phagocytic receptor on macrophages. 
We did not examine its role in the phagocytosis of C. sordellii, and this will be a subject of 
future research. We also did not identify a major role for CBSRs in the phagocytosis of C. 
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sordellii using monoclonal antibodies to block CD36 and CD163. This approach has 
limitations, and future studies using genetically-deficient, mouse-derived macrophages or 
gene-silencing approaches would be necessary to confirm our results. It is notable that human 
DMs express relatively high levels of mRNA for the CBSR CD163 (transcripts for CD163 
were the highest of all SRs we examined by semi-quantitative real time PCR (Fig. 1B)). The 
CD163 receptor is involved primarily in the clearance of hemoglobin-haptoglobin complexes 
(31). It has been implicated in anti-inflammatory responses and is a surface marker of 
alternative (M2) macrophage activation (31). Thus, our finding of CD163 expression by 
human DMs provides further support to other studies demonstrating that DMs exhibit 
features of alternative activation (17, 23). The implications of this for bacterial infections in 
the postpartum or post-abortion period are unclear.  
In summary, we newly characterize SR expressed by human DMs and their relative 
importance in the recognition and internalization of the toxigenic pathogen C. sordellii. 
Using a combination of in vitro and in vivo experiments, we demonstrate a role for MARCO 
in reproductive tract innate immunity. DMs are of paramount importance in host defense 
against bacterial infection and also regulate immunity at the fetal/maternal interface to induce 
tolerance of the fetus by the mother (26). Few studies have specifically examined host-
microbial interactions between invading bacterial pathogens and FRT macrophages. These 
results may prove to be important not only for understanding the pathogenesis of invasive 
clostridial infections, but also for developing better preventive and therapeutic measures 
against a range of both sexually and non-sexually transmitted infections.  
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 From: eSiriusWebServer <esirius-ucuca@med.umich.edu>  
To: <daronoff@umich.edu>  
Date: 5/14/2008 12:26 PM  
Subject: Approval Letter for UCUCA application #10044  
 
CC: <oconnord@umich.edu>  
 
PI: Aronoff, David M  
Protocol Number: #10044  
Approval Period: 05/14/2008 - 05/14/2011  
Funding Agency: National Institutes of Health  
Title: Role of Misoprostol in Clostridium sordellii Endometritis After Medical Abortion  
DRDA Number:  
 
Date: 05/14/2008  
 
Dear Principal Investigator,  
 
The University of Michigan Committee on Use and Care of Animals (UCUCA) has reviewed your application 
to use vertebrate animals (Application #10044). This project has been approved. The proposed animal use 
procedures are in compliance with University guidelines, State and Federal regulations, and the standards of the 
"Guide for the Care and Use of Laboratory Animals."  
 
When communicating with the UCUCA Office please refer to the Approval Number #10044. The approval 
number must accompany all requisitions for animals and pharmaceuticals.  
 
The approval date is 05/14/2008. The approval period is for three years from this date. However, the United 
States Department of Agriculture (USDA) requires an annual review of applications to use animals. Therefore, 
each year of this application prior to the anniversary of its approval date, you will be notified via email to 
submit a short annual review. Your continued animal use approval is contingent upon the completion and return 
of this annual review. You will also be notified 120 days prior to the expiration of the approval period so that 
your renewal application can be prepared, submitted and reviewed in a timely manner in the eSirius program 
and an interruption in the approval status of this project avoided.  
 
UCUCA approval must be obtained prior to changes from what is originally stated in the protocol. An 
amendment must be submitted to the UCUCA for review and approved prior to the implementation of the 
proposed change.  
 
The University's Animal Welfare Assurance Number on file with the NIH Office of Laboratory Animal Welfare 
(OLAW) is A3114-01, and most recent date of accreditation by the Association for the Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC, Intl.) is November 14, 2005.  
 
If you receive news media inquiries concerning any aspect of animal use or care in this project, please contact 
James Erickson, News and Information Services, 647-1842. If you have security concerns regarding the animals 
or animal facilities, contact Bill Bess, Director of Public Safety, 763-3434.  
 
Sincerely,  
 
Susan Stern, MD  
Associate Professor, Emergency Medicine  
Chairperson, University Committee on Use and Care of Animals  
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Medical School Institutional Review Board (IRBMED) • Argus I Building, 517 W. William, Ann Arbor, MI 48103-4943 • 
phone (734) 763 4768 • fax (734) 
763 9603 • irbmed@umich.edu 
 
To: Dr. David Aronoff 
 
From: 
Michael Geisser 
John Weg 
 
Cc: 
David Aronoff 
Laura Castleman 
Rita Loch-Caruso 
Jason Bell 
Lisa Harris 
 
Subject: Scheduled Continuing Review [CR00012813] Approved for 
[HUM00008514] 
 
SUBMISSION INFORMATION: 
Study Title: Regulation of innate immunity in the female reproductive tract 
by misoprostol: impact on Clostridium sordellii infection following abortion 
Full Study Title (if applicable): 
Study eResearch ID: HUM00008514 
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2009 
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NOTICE OF IRB APPROVAL AND CONDITIONS: 
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2:51:29 PM 
https://eresearch.umich.edu/eresearch/Doc/0/QUO1NE4HFP7K9CHPJ2KILMP4F2/fromString.html 
The IRBMED has reviewed and approved the scheduled continuing review 
(SCR) submitted for the study referenced above. The IRB determined that 
the proposed research continues to conform with applicable guidelines, State 
and federal regulations, and the University of Michigan's Federalwide 
Assurance (FWA) with the Department of Health and Human Services (HHS). 
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You must conduct this study in accordance with the description and 
information provided in the approved application and associated documents. 
 
APPROVAL PERIOD AND EXPIRATION DATE: 
The updated approval period for this study is listed above. Please note the 
expiration date. If the approval lapses, you may not conduct work on this 
study until appropriate approval has been reestablished, except as necessary 
to eliminate apparent immediate hazards to research subjects or others. 
Should the latter occur, you must notify the IRB Office as soon as possible. 
 
IMPORTANT REMINDERS AND ADDITIONAL INFORMATION FOR 
INVESTIGATORS 
APPROVED STUDY DOCUMENTS: 
You must use any date-stamped versions of recruitment materials and 
informed consent documents available in the eResearch workspace 
(referenced above). Date-stamped materials are available in the “Currently 
Approved Documents” section on the “Documents” tab. In accordance with 
45 CFR 46.111 and IRB practice, consent document(s) and process are 
considered as part of Continuing Review to ensure accuracy and 
completeness. The dates on the consent documents, if applicable, have been 
updated to reflect the date of Continuing Review approval. 
 
RENEWAL/TERMINATION: 
At least two months prior to the expiration date, you should submit a 
continuing review application either to renew or terminate the study. Failure 
to allow sufficient time for IRB review may result in a lapse of approval that 
may also affect any funding associated with the study. 
 
AMENDMENTS: 
All proposed changes to the study (e.g., personnel, procedures, or 
documents), must be approved in 
advance by the IRB through the amendment process, except as necessary to 
eliminate apparent immediate hazards to research subjects or others. Should 
the latter occur, you must notify the IRB Office as soon as possible. 
 
AEs/ORIOs: 
You must continue to inform the IRB of all unanticipated events, adverse 
events (AEs), and other reportable information and occurrences (ORIOs). 
These include but are not limited to events and/or information that may have 
physical, psychological, social, legal, or economic impact on the research 
subjects or others. 
 
Investigators and research staff are responsible for reporting information 
concerning the approved research to the IRB in a timely fashion, 
understanding and adhering to the reporting guidance (http:// 
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www.med.umich.edu/irbmed/ae_orio/index.htm ), and not implementing any 
changes to the research without IRB approval of the change via an 
amendment submission. When changes are necessary to eliminate apparent 
immediate hazards to the subject, implement the change and report via an 
ORIO and/or amendment submission within 7 days after the action is taken. 
This includes all information with the potential to impact the risk or benefit 
assessments of the research. 
 
SUBMITTING VIA eRESEARCH: 
https://eresearch.umich.edu/eresearch/Doc/0/QUO1NE4HFP7K9CHPJ2KILMP4F2/fromString.html (2 of 3)8/11/2010 
2:51:29 PM 
https://eresearch.umich.edu/eresearch/Doc/0/QUO1NE4HFP7K9CHPJ2KILMP4F2/fromString.html 
You can access the online forms for continuing review, amendments, and 
AE/ORIO reporting in the eResearch workspace for this approved study, 
referenced above. 
 
MORE INFORMATION: 
You can find additional information about UM’s Human Research Protection 
Program (HRPP) in the Operations Manual and other documents available at: 
www.research.umich.edu/hrpp. 
 
Michael Geisser 
Co-chair, IRBMED 
John Weg 
Co-chair, IRBMED 
https://eresearch.umich.edu/eresearch/Doc/0/QUO1NE4HFP7K9CHPJ2KILMP4F2/fromString.html (3 of 3)8/11/2010 
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